Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells by  et al.
Comparison of defined culture systems for feeder cell free
propagation of human embryonic stem cells
The International Stem Cell Initiative Consortium &
Veronika Akopian & Peter W. Andrews & Stephen Beil &
Nissim Benvenisty & Jennifer Brehm & Megan Christie &
Angela Ford & Victoria Fox & Paul J. Gokhale &
Lyn Healy & Frida Holm & Outi Hovatta &
Barbara B. Knowles & Tenneille E. Ludwig &
Ronald D. G. McKay & Takamichi Miyazaki &
Norio Nakatsuji & Steve K. W. Oh & Martin F. Pera &
Janet Rossant & Glyn N. Stacey & Hirofumi Suemori
Received: 11 January 2010 /Accepted: 15 January 2010 /Published online: 26 February 2010 / Editor: P. Andrews
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract There are many reports of defined culture
systems for the propagation of human embryonic stem
cells in the absence of feeder cell support, but no previous
study has undertaken a multi-laboratory comparison of
these diverse methodologies. In this study, five separate
laboratories, each with experience in human embryonic
stem cell culture, used a panel of ten embryonic stem cell
lines (including WA09 as an index cell line common to all
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DOI 10.1007/s11626-010-9297-zlaboratories) to assess eight cell culture methods, with
propagation in the presence of Knockout Serum Replacer,
FGF-2, and mouse embryonic fibroblast feeder cell layers
serving as a positive control. The cultures were assessed for
up to ten passages for attachment, death, and differentiated
morphology by phase contrast microscopy, for growth by
serial cell counts, and for maintenance of stem cell surface
marker expression by flow cytometry. Of the eight culture
systems, only the control and those based on two com-
mercial media, mTeSR1 and STEMPRO, supported main-
tenance of most cell lines for ten passages. Cultures grown
in the remaining media failed before this point due to lack
of attachment, cell death, or overt cell differentiation.
Possible explanations for relative success of the commercial
formulations in this study, and the lack of success with
other formulations from academic groups compared to
previously published results, include: the complex combi-
nation of growth factors present in the commercial
preparations; improved development, manufacture, and
quality control in the commercial products; differences in
epigenetic adaptation to culture in vitro between different
ES cell lines grown in different laboratories.
Keywords Humanembryonicstemcell.Cellculture.
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Introduction
The potential for the use of human embryonic stem cells
(hESC) and human-induced pluripotent stem (hiPS) cells in
research and therapy is widely recognized, but progress in
the field depends critically on well-characterized systems
for stem cell growth and differentiation. The original
culture systems for the derivation and maintenance of
hESC employed basal medium supplemented with fetal calf
serum and mouse embryonic fibroblast feeder cell layer
support (Thomson et al. 1998; Reubinoff et al. 2000). The
presence of undefined components of animal origin in these
systems is problematic, for two main reasons. First, unknown
factors present in serum or produced by the feeder cell layers
may confound interpretation of studies of the effect of
exogenous agents on the growth and differentiation of the
stem cells. Second, components such as serum, growth
factors, and feeder cells are prone to significant variability
and better defined and more reproducible media will enhance
standardization and help to minimize variation in stem cell
cultures. It is also desirable to eliminate animal products as
they may have the potential for transmission of pathogens to
the cultured cells, presenting a barrier to future clinical
application of hESC derivatives in therapy.
For these reasons, many research groups have set about
developing more standardized and defined media formula-
tions, sometimes based on the analysis of signaling systems
required for hES self-renewal [reviews see (Chase and
Firpo 2007; Unger et al. 2008)]. While most of the these
studies have carefully validated the new formulations for
the ability to support long-term maintenance of hESC, in
general the reports focus on one or two cell lines often
grown in the laboratory of origin. It remains unclear how
robust are the different formulations, whether some perform
better than others, whether a particular formulation will
support a wide variety of cell lines, and how easy it is to
transfer the published protocols between laboratories. There
is a strong rationale for identifying a few common tissue
culture platforms for hESC and hiPS cells, to enable
development of standardized protocols for stem cell growth
and differentiation, and to facilitate comparisons of studies
between cell lines and between laboratories.
The International Stem Cell Initiative is a consortium of
laboratories founded to help establish standards for plurip-
otent stem cell research (Andrews et al. 2005). Following a
major survey of the phenotype of a large number of hESC
isolates (Adewumi et al. 2007), the consortium decided to
undertake a comparative study of defined culture systems
for hESC growth. Participant laboratories were polled to
identify a short list of the most promising formulations for
study. The media chosen for study range from relatively
simple formulations such as hESF9 which consists of a
basal medium and FGF-2 supplemented with heparin
sulfate (Furue et al. 2008), through complex media such
as mTeSR1 (Ludwig et al. 2006a, b) and STEMPRO (Wang
et al. 2007) which utilize several growth factors or chemicals
which can mimic growth factor signaling to promote hES
cell growth. The media often contain additives that serve as
substitutes for serum-derived components, for example
transferrin, albumin, cholesterol, and lipid mixtures. While
all media we tested contained growth factors, there was a
high degree of variation in the growth factors and concen-
trations used. For example, fibroblast growth factor was a
component in all media but at a range of concentrations. The
two most complex media in terms of growth factors and
signaling agonists added were the commercial media
mTeSR1 (Ludwig et al. 2006b) and STEMPRO (Wang
et al. 2007). Interestingly, while both these media use
stimulation of the FGF and TGF-beta pathway via FGF-2
and TGF-beta in mTeSR1 and FGF and ActivinA in
STEMPRO, they also utilize alternate signaling pathways
in addition to these two. mTeSR1 uses a GABA agonist
and the non-specific WNT antagonist lithium chloride
(Klein and Melton 1996), while STEMPRO uses the
ErbB2 ligand HRG1beta and the insulin growth factor
ligand LR3-IGF1.
This study addressed the ability of these diverse
formulations to support hESC growth in academic labora-
tories experienced in hESC culture technology.
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Study Design. A meta-analysis of published methods in-
cluding patent literature was conducted to identify likely
candidate media. From this analysis, eight different culture
systems (Li et al. 2005; Vallier et al. 2005; Liu et al. 2006;
Lu et al. 2006;L u d w i ge ta l .2006a, b; Yao et al. 2006;
Wang et al. 2007) were selected for further study by
consortium laboratories. The media were designed to replace
any feeder cell requirement, and extracellular matrix compo-
nents were included as indicated by the laboratory of origin.
Four laboratories were recruited to conduct the initial
study (see Table 1). These laboratories were asked to
conduct tests using two cell lines from their own laboratory
and also a centrally supplied reference cell line provided by
WiCell, WA09 (Thomson et al. 1998). Cultivation of cells
in the presence of Knockout Serum Replacer supplemented
with FGF-2 in the presence of a mouse embryonic
fibroblast feeder cell layer (Amit and Itskovitz-Eldor
2006) served as a positive control. Key components for
the selected culture systems (such as growth factors and
specialized additives) were purchased centrally and shipped
to participating laboratories. The formulated media (or
supplied commercial products) were tested in standardized
cell attachment, survival, and maintenance (five to ten
passages) assays using a small number of selected lines in
the 4 central laboratories. Each culture in defined medium
was initiated by seeding cells from stock cultures maintained
under standard conditions used the test laboratory—generally
culture on feeder cells in KSR-based media—with no
allowance made to adapt cells to each of the new test media
prior to the study. At each passage, the cells were seeded
into multiple wells of a 6-well tissue culture plate, allowing
replicate analyses as required during the trial. Protocols
for cell culture, prepared by reference to the original
published description of the defined media, and flow
cytometry, were distributed to all participant groups. Details
of these protocols may be found on the ISCI website (www.
stemcellorg.com).
Once the original tests were completed, an independent
laboratory (UK Stem Cell Bank, NIBSC-HPA) repeated
studies on medias 1–6, using the original growth factor
reagents, or newly purchased and formulated reagents, and
in one case, fully supplemented medium ready to use,
Table 1. Summary of laboratories and cell lines used in the study
Lab CODE Cell lines
Kyoto University KYOU WA09 (H9) KhES-1 KhES-3
Karolinska Institute (KI) KLNI WA09 (H9) HS181 HS420
WiCell WCEL WA09 (H9) WA13 (H13) ES03 (HES3) WA01 (H1)
CSCRM, University of Southern California KUSC WA09 (H9) ES03 (HES3) ES04 (HES4)
UK Stem Cell Bank UKSCB WA09 (H9) HUES9 NCL5 Shef2
Table 2. Summary of media and passaging regimes used in this study
Media no. Media
name
Reference Passaging
enzyme
Matrix Notes
1 (Li et al. 2005) Dispase Geltrex or Matrigel
2 (Liu et al. 2006) Dispase Geltrex or Matrigel
3 (Vallier et al. 2005) Dispase Gelatin, MEF CM, 10% FBS Use in 5% CO2 only. Passage when
colonies 4–6 times size passaged from
MEF-based cultures. Fibronectin
can be used as alternative to FBS.
4 (Lu et al. 2006) Dispase Geltrex or Matrigel
5 (Yao et al. 2006) Dispase Geltrex or Matrigel
6 hESF9 (Furue et al. 2008) EDTA, 0.2% Collagen IA (Nitta Gelatin
a) Passage day 2 after first passage, thence
every 5 d. EDTA/Collagenase can used
as alternative passaging reagents.
7 mTeSR1 (Ludwig et al. 2006a) Dispase Geltrex or Matrigel Passage when colonies begin to merge
together
8 STEMPRO (Wang et al. 2007) Dispase Geltrex or Matrigel Harvest cells 1–2 d after colonies touch.
Maintain at >200 colonies/60 mm dish
aNitta Geletin: Type I Collagen (Cellmatrix, Cell Science & Technology Institute, Inc. Japan)
COMPARISON OF DEFINED CULTURE SYSTEMS 249supplied directly from the laboratory of origin of the
formulation. The repeated testing was carried out on, with
the independent cell lines HUES9, NCL5 and Shef2, and the
H9 cell line common to all the laboratories (Table 1). The
passaging regimes used in the study for each medium are
summarized in Table 2.
Media Formulations. The formulations of the various test
media, based on the published descriptions, are summarized
in Table 3. A summary of the sources of the components
that were used to formulate the different growth media is
listed in Table 4.
Cell Growth. At each passage, three replicate wells of a
6-well plate were harvested with trypsin/EDTA, the cells
were resuspended in PBSA containing trypan blue dye, and
a viable cell count was performed.
Flow Cytometry. Flow cytometry analysis was carried out
for nine cell surface antigens including eight markers of
primate pluripotent stem cells and one differentiation
marker as described elsewhere (Adewumi et al. 2007).
2102Ep human embryonal carcinoma cells were used as a
positive control (Andrews et al. 1982; Josephson et al.
2007).
Table 3. Summary of media formulations used in the study
Media no. 1 2 3 4 5 6 7 8
KO-DMEM
XVIVO-10 ✓
DMEM/F12 ✓✓ ✓ ✓
b ✓
IMDM/F12 ✓
ESF
a ✓
N2 ✓✓
B27 ✓✓
NEAA 1% 1% ✓✓ 1×
L-glutamine 2 mM 1 mM 4 mM 1 mM 2 mM 2.94 mM 542 mg/l
Beta-MercaptoEthanol 0.1 mM 0.1 mM 0.11 mM 10 µM 0.098 mM 0.1 mM
Insulin 7 µg/ml 160 µg/ml 10 µg/ml 3.92 µM
Transferrin 15 µg/ml 88 µg/ml 5 µg/ml 0.137 µM 10 µg/ml
2-ethanolamine 10 µM
Na-selenite 20 nM
L-ascorbic acid
2-phosphate
0.1 mg/ml
Monothioglycerol 450 μM
Cholesterol ✓ 1.12 µM
Lipids ✓ Oleic acid
c ✓ Lipoic acid
0.105 mg/l
BSA 5 mg/ml 0.5 mg/ml ✓ 0.195 mM 2 %
Pipecolic Acid 0.984 µM
Activin A 10 ng/ml 10 ng/ml
bFGF 40 ng/ml 100 ng/ml 12 ng/ml 4 ng/ml 20 ng/ml 10 ng/ml 100 ng/ml 8 ng/ml
WNT3A 100 ng/ml
hFLT3 15 ng/ml
HRG1β 10 ng/ml
LR3-IGF1 200 ng/ml
BAFF 100 ng/ml
TGF-beta 23.5 pM
GABA 0.979 mM
LiCl 0.98 mM
Na Heparin SO4 ✓
aBase medium ESF designed for use with mouse ES cells (Furue et al. 2008)
bModified DMEM/F12 (Ludwig et al. 2006b)
cConjugated with fatty acid free BSA (9.4 µg/ml)
250 THE INTERNATIONAL STEM CELL INITIATIVE CONSORTIUM ET AL.Table 4. Summary of sources of media components
Media no. Media name Reference Component Manufacturer Catologue no.
1 (Li et al. 2005) XVIVO-10 Lonza
NEAA Invitrogen 11140-050
L-glutamine Invitrogen 25030-081
Beta-mercaptoethanol Invitrogen 21985-023
hbFGF RnD Systems 3718-FB
hFLT3 RnD Systems 308-FKN/CF
2 (Liu et al. 2006) DMEM/F12 Invitrogen 21041-025
N2 Invitrogen 17502-048
B27 Invitrogen 17504-044
L-glutamine Invitrogen 25030-081
Beta-mercaptoethanol Invitrogen 21985-023
hbFGF RnD Systems 3718-FB
3 (Vallier et al. 2005) IMDM Invitrogen 21980-32
F12 Invitrogen 31765-027
L-glutamine Invitrogen 25030-081
Beta-mercaptoethanol Invitrogen 21985-023
Insulin Invitrogen 12585-014
Transferrin Invitrogen 11105-012
Monothioglycerol Sigma-Aldrich M6145
BSA Europa bioproducts EQBAC62 - lot BAC62-624
ActivinA RnD Systems 338-AC/CF
hbFGF RnD Systems 3718-FB
4 (Lu et al. 2006) DMEM/F12 Invitrogen 21041-025
L-glutamine Invitrogen 25030-081
Beta-mercaptoethanol Invitrogen 21985-023
Insulin Invitrogen 12585-014
Transferrin Invitrogen 11105-012
Cholesterol Invitrogen 12531-018
Albumin Invitrogen 11021-029
hbFGF RnD Systems 3718-FB
WNT3A RnD Systems 1324-WN/CF
BAFF Invitrogen PHC1674
5 (Yao et al. 2006) DMEM/F12 Invitrogen 21041-025
N2 Invitrogen 17502-048
B27 Invitrogen 17504-044
NEAA Invitrogen 11140-050
L-glutamine Invitrogen 25030-081
Beta-mercaptoethanol Invitrogen 21985-023
BSA Fraction V Invitrogen 15260-037
hbFGF RnD Systems 3718-FB
6 hESF9 (Furue et al. 2008) n/a CSTI
7 mTeSR1 (Ludwig et al. 2006a) n/a Stem Cell Technologies
8 STEMPRO (Wang et al. 2007) n/a Invitrogen
Addresses of suppliers:
Invitrogen Corporation, 5791 Van Allen Way, Carlsbad, CA 92008, USA.
RnD Systems Inc., 614 McKinley Place N.E., Minneapolis, MN 55413, USA.
Stem Cell Technologies 570 West Seventh Avenue, Suite 400, Vancouver, BC, Canada V5Z 1B3
CSTI: Cell Science & Technology Institute, Inc 982-0262 1-chome, Aoba-ku, Sendai, Miyagi, Japan.
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Figure 1. (A)S u m m a r yt e s t
results. (B) Results of the retest
of the media by UKSCB. For
most tests new growth factors
were obtained however for
testing of medium no. 3 three
different batches of Activin A
were used. ISCI-GF: Original
growth factor batch used in the
ISCI study. UKSCB-GF: New
Growth factor obtained for the
retest. LV-GF: Activin A
obtained from the originating
laboratory.
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Overall Summary of Attachment, Survival, Growth, and Stem
Cell Maintenance. Figure 1A displays a chart summarizing
the fate of hESC cultures grown in the test media by four
laboratories over the course of the study. Results from the
four laboratories were generally consistent. Most of the test
media failed to support long-term maintenance of stem cell
cultures under the conditions of this study. Cultures either
failed to initiate or attach in the test media or terminated
after passages 2–5 with poor attachment or death or more
frequently, morphological appearance of differentiation. By
contrast, in all laboratories, mTeSR1 and STEMPRO, and
the positive control culture system, all supported stem cell
maintenance throughout ten passages. Phase contrast
images of hESC colonies that were grown successfully
using these media are shown in Fig. 2.
To determine whether or not the failures observed related
to a particular batch of test reagents, a fifth laboratory
repeated some of the tests on a panel of cell lines using a
new set of reagents. The results were similar to those
obtained by the four laboratories that originally carried out
the study; showing inability of medias 1-6 to support cell
line growth beyond a maximum of 5 passages Fig. 1B.
Figure 1. (continued).
COMPARISON OF DEFINED CULTURE SYSTEMS 253Interestingly, however, one medium formulation (Vallier et
al. 2005), obtained fully supplemented directly from the
laboratory of origin with minimal shipment, performed
better than either batch formulated by the test laboratory.
Growth Curves. Representative growth curves illustrating
results from several different cell lines are shown in Fig. 2.
Consistent cell yields were sustained for ten passages only
in the control conditions and with the two commercial
media, mTeSR1 and STEMPRO. Of the other media, it is
notable that no. 2 and no. 5 performed better than some of
the others under these conditions.
Flow Cytometry. Quantitative analysis of cell surface
antigen expression was carried out at passages 0 and 5
and 10 for those cell lines and culture systems that
maintained growth to those time points. Representative
data are shown in Fig. 3. The results generally were in line
with the overall morphological observations of the cultures
and the data on the maintenance of cell numbers. Thus, the
positive control and the two commercial defined media
supported stem cell maintained expression of stem cell
markers. Again the media no. 2 and no. 5 showed main-
tenance of stem cell markers in some cell lines in some
laboratories for up to five passages (data not shown).
Discussion
This study demonstrates that culture of hESC in defined
media without feeder cells is not a trivial undertaking even
for laboratories with significant experience in the field. Apart
from the commercial preparations, most of the formulations
did not support maintenance of hESC for even the relatively
short period of this study. Retesting of the media that failed
to support stem cell maintenance by an independent
laboratory, using freshly formulated growth factors, indicated
that it was unlikely that the outcomes were due to problems
specific to the preparations used in the original studies, but
rather to a general difficulty in preparing these media. It is
notable however that while the independent laboratory had
difficulties with media no. 3, their results were substan-
tially better when they used this medium supplied direct
by the laboratory of origin, suggesting a critical need for
selecting reagent batches and/or subtleties in media
preparation.
B
Figure 1. (continued).
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nodal/TGF-beta signaling are critical for hESC maintenance
(Beattie et al. 2005; James et al. 2005; Vallier et al. 2005,
2009; Xiao et al. 2006; Greber et al. 2007; Xu et al. 2008).
Of the formulations tested, only TeSR, Stem Pro, and no. 3
contain agonists for both pathways: of these, the two
commercial media, mTeSR1 and STEM PRO, were the
most successful in supporting stem cell growth. These
commercial media also contained agonists of other signal-
ing systems, such as GABA receptors and ErbB2, which
CELL
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1.00
.00
PASSAGE
10 9 8 7 6 5 4 3 2 1
CELL
COUNT/10^6
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1.00
.00
STEMPRO
mTeSR1
KhES-3
KhES-1
H9 (WA09)
CELL LINE
STEMPRO
H9
mTeSR1
KhES-1 A
B
Figure 2. Representative pho-
tomicrographs and cell counts.
(A) Photomicrographs of
KhES-1 and H9 (WA09)
respectively grow to ten
passages in mTeSR1 and
STEMPRO, respectively.
(B) Representative cell counts
from each passage for the cell
lines WA09 (H9), KhES-1,
and KhES-3.
COMPARISON OF DEFINED CULTURE SYSTEMS 255while less well characterized, are thought to play a role in
hESC maintenance.
Considerable effort in development, manufacture, and
quality control goes into the formulation and production of
commercial media, and it may be that it is difficult to
implement equivalent reproducibility in the context of an
academic laboratory, particularly when transferring a
medium preparation process to many laboratories. This
factor might account for the relative success of the com-
mercial preparations observed in our study. On the other
hand, there are ample reports of successful long-term pro-
pagation of hESC in media supplemented with FGF-2,
or other reagents, from a number of different academic
laboratories, and the only preparation required of the test
laboratories in this study was addition of factors and a few
other components to manufactured basal media.
Another explanation for the variability of outcomes ob-
served here compared to published results might lie in the
hESC themselves. hESC produce a number of polypeptides
that can influence their growth and differentiation. Both
FGF and nodal are expressed in hESC cultures (Sperger
et al. 2003; Sato et al. 2003; Ginis et al. 2004), as are
antagonists of nodal/activin signaling (Brandenberger et al.
2004), as well as BMPs, which activate SMAD1/5/8 signal-
ing to drive hESC differentiation (Sato et al. 2003). Differ-
ences in production of such factors might reflect subtle
differences in methods of passaging (e.g., sizes of cell
clumps that are passaged), which are difficult to standardize
between laboratories or glean from published details. It is
also possible that epigenetic adaptation in vitro leads to
modulation of the activity of these pathways in hESC
cultures, and that this process varies between different cell
lines, or even between the same cell line maintained in
different laboratories. In particular genotypic and epigenetic
differences between cell lines may give rise to differences in
the expression levels of different receptor subtypes such as
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Figure 3. Representative flow
cytometry data. Representative
flow cytometry data expressed
as percentage of cells called
positive for three cell lines
H9, KhES-1, and KhES-3 at
passage 0 in Knockout Serum
Replacer, FGF-2, and mouse
embryonic fibroblast feeder cells
and at passage 5 and 10 for cells
grown in mTeSR1 and
STEMPRO.
256 THE INTERNATIONAL STEM CELL INITIATIVE CONSORTIUM ET AL.FGF and TGF-beta receptors and cell attachment modulators
such as the Integrin family of receptors. Changes in cell
surface receptor expression and cell adhesion modulators
between cell lines or indeed at different phases of the hESC
culture regrowth may necessitate that different hESC isolates
have quite distinct exogenous factor requirements in a given
growth media to achieve proper cell adhesion and mainte-
nance of the undifferentiated state. It would be possible to
compare the endogenous activity of some of these critical
signaling pathways between ES cell lines and sublines and
then relate this to dependence upon exogenous factors.
Whatever the role of endogenous autocrine or paracrine-
signaling in hESC maintenance, the activation of multiple
pathways driving stem cell maintenance and the inhibition
of pathways that drive differentiation by combinations of
agonists/antagonists with distinct mechanisms of action rep-
resent a robust strategy for development of defined culture
systems.
Conclusions
Eight different defined culture systems were assessed in a
multicenterstudyfortheirabilitytosupporthESCmaintenance
for ten passages. Two commercial media, mTeSR1 and
STEMPRO, consistently functioned well in assays of growth
andstemcellmaintenancethroughoutthedurationofthestudy.
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